Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
about
Paroxysmal nocturnal hemoglobinuria from bench to bedsideRole of Complement in Autoimmune Hemolytic AnemiaNew Insights in the Pathogenesis of Autoimmune Hemolytic AnemiaComplement inhibitors to treat IgM-mediated autoimmune hemolysisTreatment of autoimmune hemolytic anemiasRed blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapyGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab.How I manage cold agglutinin disease.Brown Recluse spider bite mediated hemolysis: clinical features, a possible role for complement inhibitor therapy, and reduced RBC surface glycophorin A as a potential biomarker of venom exposure.Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.Classification and therapeutic approaches in autoimmune hemolytic anemia: an update.Current approaches for the treatment of autoimmune hemolytic anemia.The expanding role of therapeutic antibodies.Current treatment strategies in autoimmune hemolytic disorders.Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy.Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity.Long-term response of refractory primary cold agglutinin disease to eculizumab therapy.Recurrent Donath-Landsteiner hemolytic anemia: a pediatric case report.The diagnosis and management of primary autoimmune haemolytic anaemia.Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways.Acute autoimmune hemolytic anemia due to anti-Ena autoantibody successfully treated with rituximab.Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.Fatal warm autoimmune hemolytic anemia in a child due to IgM-type autoantibodies.Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation.
P2860
Q24599629-A3F814FB-AD21-48A2-8C81-DBA0F2017442Q26773175-749DF811-DCAF-4AA0-A46E-3C16EBB396F0Q26773181-AF45A1F1-A72D-443B-9F85-F0CAF38676C1Q26777628-2364B094-E159-4135-9D1E-49483773B64FQ26866954-2482251E-6924-4E6B-A7AE-90521C22E253Q27013581-C3A4D207-0BDA-4742-A025-BA4DADB5ED79Q30276550-5D668B37-4341-4E45-90CB-3F32219D7EC5Q33699006-28BA7E43-B990-4B48-A470-539ED83E4B9BQ34169220-227A5241-565A-4150-9D48-863A55DB6AC1Q35006388-2C774C79-452D-4656-8929-A479DAF20AF2Q37924893-687E797E-BCC5-4E56-BA87-4E11BAB9AE28Q37955228-198749BF-BE9F-4B4A-9BC8-04C2C91D7354Q38108152-F24AA9B9-048B-482B-8345-B1B740C3AC94Q38182645-0026783E-72E5-4178-8E90-0243915352EBQ38581833-3FEA10A9-0846-4B1C-B552-4BADE8DEF16EQ39862648-586A63A1-6CE3-4BEF-89BC-2AD4743FAE3AQ43180059-F37FFEDD-BF5C-4A52-B504-F2815EC89EFCQ45970786-E2CB47A2-CB61-42F7-A610-4E85EF31EA7DQ47830076-7314C51B-8EB0-49CF-86DD-AF79337143DFQ48124799-CBBEE35C-6C6A-47B1-80E7-C95079F0F3E5Q48371887-BD0AB25C-C609-4F03-8485-B99C5B73A15FQ50098670-0723BC69-11EA-46B6-888B-F1B517AE214DQ50445091-29A4082D-E43F-442A-B32E-5E86D9DBA1FFQ51511360-ECEA1FD5-B54D-4BD2-9244-EFCFD7619937Q52839308-F699F088-3267-43B6-BD7B-5A8B6F6E6B9B
P2860
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
description
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2009
@ast
im April 2009 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 16 April 2009)
@en
vedecký článok (publikovaný 2009/04/16)
@sk
vědecký článek publikovaný v roce 2009
@cs
wetenschappelijk artikel (gepubliceerd op 2009/04/16)
@nl
наукова стаття, опублікована у квітні 2009
@uk
مقالة علمية (نشرت في 16-4-2009)
@ar
name
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
@ast
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
@en
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
@nl
type
label
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
@ast
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
@en
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
@nl
prefLabel
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
@ast
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
@en
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
@nl
P2093
P3181
P1433
P1476
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
@en
P2093
Alexander Röth
Andreas Hüttmann
Russell P Rother
Thomas Philipp
Ulrich Dührsen
P304
P3181
P356
10.1182/BLOOD-2009-01-196329
P407
P577
2009-04-16T00:00:00Z